As of 3:59pm ET
| +0.0063 / +1.40%|
The 3 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.70. The median estimate represents a +64.37% increase from the last price of 0.46.
The current consensus among 3 polled investment analysts is to Hold stock in CTi Biopharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.